The study aims to understand how well different treatments work for people with multiple myeloma (MM), a blood cancer. There are two groups: those newly diagnosed (NDMM) and those whose cancer has returned or didn't respond to treatment (RRMM). The study looks at real-life treatment outcomes and does not provide any new treatment itself. If you join, your doctor will decide your treatment, but your progress will help researchers learn more about MM therapies.

To join, if you have RRMM, you must have tried at least one other treatment before, like IMiDs (immunomodulatory drugs) or PIs (proteasome inhibitors). If you are newly diagnosed, you should be eligible for first-time treatment. You can’t join if you’re in another trial, have another primary cancer, or can't give consent.

• The study is observational, meaning it does not change your treatment plan.
• No new medications are provided; it evaluates existing approved therapies.
• Your information will help improve understanding of MM treatment effectiveness.